Inogen (NASDAQ:INGN) Rating Increased to Sell at BidaskClub

BidaskClub upgraded shares of Inogen (NASDAQ:INGN) from a strong sell rating to a sell rating in a research note released on Saturday morning, BidAskClub reports.

INGN has been the topic of several other research reports. Needham & Company LLC raised shares of Smart Global from a hold rating to a buy rating and set a $32.00 target price on the stock in a research note on Friday, June 28th. Stifel Nicolaus raised shares of Protagonist Therapeutics from a hold rating to a buy rating and lifted their price objective for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an overweight rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $117.60.

INGN stock opened at $63.18 on Friday. The firm has a market cap of $1.39 billion, a PE ratio of 27.47, a PEG ratio of 2.43 and a beta of 1.45. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. The business has a 50-day moving average price of $64.69. Inogen has a fifty-two week low of $56.83 and a fifty-two week high of $287.79.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, May 7th. The medical technology company reported $0.24 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.05). The company had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a net margin of 12.56% and a return on equity of 15.59%. The firm’s quarterly revenue was up 14.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.48 EPS. On average, analysts expect that Inogen will post 1.63 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Marshall Wace LLP boosted its stake in shares of Inogen by 180.2% in the 1st quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock valued at $5,301,000 after purchasing an additional 35,747 shares in the last quarter. Geode Capital Management LLC lifted its position in Inogen by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 205,160 shares of the medical technology company’s stock worth $25,474,000 after buying an additional 16,183 shares in the last quarter. Legal & General Group Plc lifted its position in Inogen by 3.9% during the 4th quarter. Legal & General Group Plc now owns 17,963 shares of the medical technology company’s stock worth $2,230,000 after buying an additional 668 shares in the last quarter. Renaissance Group LLC acquired a new position in Inogen during the 1st quarter worth about $428,000. Finally, MetLife Investment Advisors LLC lifted its position in Inogen by 52.3% during the 4th quarter. MetLife Investment Advisors LLC now owns 18,341 shares of the medical technology company’s stock worth $2,277,000 after buying an additional 6,302 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: Forex

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.